近日，创胜集团医药-B（06628.HK）发布公告称，创胜集团全资子公司杭州奕安济世生物药业有限公司（以下简称“奕安济世”）与药明生物旗下杭州明德生物医药技术有限公司签署资产购买协议，拟作价人民币1.9亿元出售杭州医药合同研发生产机构（CDMO）相关资产，包括目标厂房土地使用权、房屋所有权、生产设备、存量业务合约等资产权益。本次交易为港交所上市规则项下主要交易，尚待股东大会批准及其他交割先决条件...
Source Link近日，创胜集团医药-B（06628.HK）发布公告称，创胜集团全资子公司杭州奕安济世生物药业有限公司（以下简称“奕安济世”）与药明生物旗下杭州明德生物医药技术有限公司签署资产购买协议，拟作价人民币1.9亿元出售杭州医药合同研发生产机构（CDMO）相关资产，包括目标厂房土地使用权、房屋所有权、生产设备、存量业务合约等资产权益。本次交易为港交所上市规则项下主要交易，尚待股东大会批准及其他交割先决条件...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.